Skip to content

Levonorgestrel Intrauterine System For Emergency Contraception

Levonorgestrel Intrauterine System For Emergency Contraception: a Randomized Control Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01539720
Acronym
LIFE
Enrollment
274
Registered
2012-02-27
Start date
2012-12-31
Completion date
2018-11-30
Last updated
2024-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy, Unplanned, Pregnancy; Accident

Keywords

emergency contraception, Ella, Mirena IUD, post-coital contraception, Liletta IUD

Brief summary

The purpose of this research study is to test the levonorgestrel intrauterine system as a method for emergency contraception. Emergency contraception refers to pregnancy prevention after an act of intercourse. While the levonorgestrel intrauterine system is approved as a contraceptive method, it is considered investigational as emergency contraception, which means that it has not been approved by the U.S. Food and Drug Administration. This study will compare the device to the most common types of emergency contraception, oral Ulipristal acetate, or oral levonorgestrel. The oral levonorgestrel regimen was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 1998. This method involves taking a 1.5mg pill of levonorgestrel in a single, one time dose. The Ulipristal acetate was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 2010. This method involves taking a 30mg pill of Ulipristal acetate in a single, one time dose.

Detailed description

Unintended pregnancy rates in the United States are among the highest of developed nations. These high rates can largely be attributed to incorrect or under contraception of women. One focus of decreasing unintended pregnancy and abortion rates has centered on expanding access to and use of long acting reversible contraceptive (LARC) methods which include intrauterine devices (IUDs) and subdermal implants. Emergency contraception, or post-coital contraception, offers significant reductions in the chance of pregnancy following an act of unprotected or under-protected vaginal intercourse. The most common methods of emergency contraception used in the United States are the oral levonorgestrel regimen and oral ulipristal acetate (Ella) regimen which reduce pregnancy risk by up to 89%. More effective, but rarely used, is the Cu T-380 intrauterine device (Copper IUD). The IUD has the added benefit of providing extended contraceptive use beyond the single episode of unprotected intercourse. The Cu-T380 has been associated with heavier and more crampy menses however, likely dissuading women from use. Among all IUD users, the levonorgestrel intrauterine system (LNG-IUS) has gained popularity over the Cu-T380, perhaps because it offers the potential to improve menstrual related symptoms. There is no data however on the efficacy of the LNG-IUS as a form of emergency contraception. The purpose of this study is to evaluate the efficacy of the LNG-IUS as a method of emergency contraception. Participants will be randomized to receive either the most common method, oral emergency contraception, or the LNG-IUS. Participants will then be evaluated 5-6 weeks following method allocation for pregnancy. Lastly, participants will be asked to complete a telephone surveys at 6 and 12 months following method allocation assessing their use of a consistent contraceptive method, their satisfaction with their contraceptive method, any use of emergency contraception since their enrollment in the study, and lastly any unintended pregnancies experienced since enrollment in the study. If we could show that the LNG-IUS is as effective as the most commonly prescribed method of emergency contraception, we would be introducing another opportunity for LARC initiation and subsequently impacting unintended pregnancy and abortion rates.

Interventions

DRUGUlipristal acetate

30 mg tablet

Levonorgestrel IUS, 52mg placed intrauterine

Sponsors

William and Flora Hewlett Foundation
CollaboratorOTHER
University of Colorado, Denver
CollaboratorOTHER
Planned Parenthood Federation of America
CollaboratorOTHER
University of Rochester
CollaboratorOTHER
Planned Parenthood of the St. Louis Region and Southwest Missouri
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
14 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Women age 14-45 * Under-protected intercourse within the last five days (120 hours) * Willingness to accept either intervention: intrauterine contraception or oral emergency contraception (EC) * Ability and willingness to follow-up for in clinic urine pregnancy test (UPT) * Ability and willingness to be contacted by phone for 6 and 12 month follow-up

Exclusion criteria

* Positive pregnancy test * Non-English speaking * Contraindication to intrauterine contraception or oral EC * Inability or unwillingness to comply with follow-up

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Pregnancy Following Emergency Contraception5 weeks post-randomizationObserved pregnancies at 5 weeks and at 6 months in the LNG-IUD group will be compared to those in the oral UPA group.

Secondary

MeasureTime frameDescription
Number of Participants Using Any LARC Method at 6 Months Post Randomization6 months post randomizationThe number of participants who reported using any type of long acting reversible contraception (LARC) use at 6 months following method allocation will be evaluated, whether or not it was their allocated LNG-IUS.
Number of Participants Reporting Continuation and Satisfaction With Their Study Allocated LNG-IUS6 months post randomizationContinuation and satisfaction among participants in the LNG-IUS arm who reported still using their LNG-IUS at 6 month post randomization.

Countries

United States

Participant flow

Participants by arm

ArmCount
Levonorgestrel Intrauterine System
Participants randomized to the levonorgestrel IUS will undergo placement at the time of randomization. They will follow-up with a self-administered urine pregnancy test 5-6 weeks following. levonorgestrel IUS: Levonorgestrel IUS, 52mg placed intrauterine
183
Ulipristal Acetate
Women in this arm will receive the oral Ulipristal acetate (Ella) regimen, which is currently the most effective method of oral emergency contraception. Ulipristal acetate: 30 mg tablet
73
Total256

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up147
Overall StudyScreen Fail153

Baseline characteristics

CharacteristicLevonorgestrel Intrauterine SystemUlipristal AcetateTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
183 Participants73 Participants256 Participants
Age, Continuous27.7 years
STANDARD_DEVIATION 6.1
27.1 years
STANDARD_DEVIATION 6.5
27.5 years
STANDARD_DEVIATION 6.2
Ethnicity (NIH/OMB)
Hispanic or Latino
15 Participants5 Participants20 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
168 Participants68 Participants236 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race/Ethnicity, Customized
Black
66 Participants40 Participants106 Participants
Race/Ethnicity, Customized
Not Reported
1 Participants0 Participants1 Participants
Race/Ethnicity, Customized
Other
23 Participants7 Participants30 Participants
Race/Ethnicity, Customized
White
93 Participants26 Participants119 Participants
Region of Enrollment
United States
183 participants73 participants256 participants
Sex: Female, Male
Female
183 Participants73 Participants256 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1830 / 73
other
Total, other adverse events
0 / 1830 / 73
serious
Total, serious adverse events
0 / 1830 / 73

Outcome results

Primary

Number of Participants With Pregnancy Following Emergency Contraception

Observed pregnancies at 5 weeks and at 6 months in the LNG-IUD group will be compared to those in the oral UPA group.

Time frame: 5 weeks post-randomization

Population: total eligible for analysis after 5-6 weeks post randomization = 256; total eligible for analysis after 6 months post randomization = 235

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Levonorgestrel Intrauterine SystemNumber of Participants With Pregnancy Following Emergency ContraceptionPregnancy at 5 weeks post randomization.0 Participants
Levonorgestrel Intrauterine SystemNumber of Participants With Pregnancy Following Emergency ContraceptionPregnancy at 6 months post randomization.0 Participants
Ulipristal AcetateNumber of Participants With Pregnancy Following Emergency ContraceptionPregnancy at 5 weeks post randomization.0 Participants
Ulipristal AcetateNumber of Participants With Pregnancy Following Emergency ContraceptionPregnancy at 6 months post randomization.6 Participants
Secondary

Number of Participants Reporting Continuation and Satisfaction With Their Study Allocated LNG-IUS

Continuation and satisfaction among participants in the LNG-IUS arm who reported still using their LNG-IUS at 6 month post randomization.

Time frame: 6 months post randomization

Population: 169 = total eligible for analysis from randomized LNG-IUS arm; at 6 months post randomization, 92 of 169 were still using LNG-IUS, so only 92 eligible to analyze satisfaction with LNG-IUS at 6 months post randomization.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Levonorgestrel Intrauterine SystemNumber of Participants Reporting Continuation and Satisfaction With Their Study Allocated LNG-IUSContinuation of LNG-IUS at 6 months92 Participants
Levonorgestrel Intrauterine SystemNumber of Participants Reporting Continuation and Satisfaction With Their Study Allocated LNG-IUSSatisfaction with LNG-IUS at 6 months82 Participants
Secondary

Number of Participants Using Any LARC Method at 6 Months Post Randomization

The number of participants who reported using any type of long acting reversible contraception (LARC) use at 6 months following method allocation will be evaluated, whether or not it was their allocated LNG-IUS.

Time frame: 6 months post randomization

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Levonorgestrel Intrauterine SystemNumber of Participants Using Any LARC Method at 6 Months Post Randomization95 Participants
Ulipristal AcetateNumber of Participants Using Any LARC Method at 6 Months Post Randomization13 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026